Viatris Inc.
VTRS Healthcare Drug Manufacturers Specialty & Generic
Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue grew 4.88%, EPS fell 2,464.1%, free cash flow grew 101.1% and total debt fell 18.1%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for five consecutive years.
Follow VTRS
Viatris Inc. (VTRS) Return on assets
Viatris Inc.'s return on assets over the twelve months to 30 June 2026 was −1.12%, up 7.8 percentage points from fiscal 2025 (−8.93%). Over the past ten years it has ranged from −8.93% (fiscal 2025) to 4.45% (fiscal 2015) — the current reading is the lowest in ten years. That is above the Drug Manufacturers Specialty & Generic industry median of −3.32% and above the Healthcare sector median of −30.9%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −8.93% | (7.51) |
| FY2024 | −1.42% | (1.53) |
| FY2023 | 0.11% | (3.85) |
| FY2022 | 3.96% | 6.14 |
| FY2021 | −2.18% | (0.74) |
| FY2020 | −1.44% | (1.49) |
| FY2019 | 0.05% | (0.98) |
| FY2018 | 1.03% | (0.94) |
| FY2017 | 1.97% | 0.29 |
| FY2016 | 1.68% | (2.77) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ZTS Zoetis Inc. compare | 17.8% |
| UTHR United Therapeutics Corporation compare | 17.3% |
| NBIX Neurocrine Biosciences, Inc. compare | 15.3% |
| RDY Dr. Reddy's Laboratories Ltd compare | 5.55% |
| TAK Takeda Pharmaceutical Co. compare | 2.15% |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 1.77% |
| HLN Haleon PLC Sponsored ADR compare | 0.00% |
| VTRS Viatris Inc. | −1.12% |
| ELAN Elanco Animal Health Incorporated compare | −1.46% |
| Drug Manufacturers Specialty & Generic industry median | −3.32% |
| Healthcare sector median | −30.9% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on VTRS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement